









Markets
/
Stocks
/
nasdaq-vvos
/

Vivos Therapeutics Inc

VVOS

2.430USD

+0.070+2.97%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

17.80MMarket Cap

LossP/E TTM



Vivos Therapeutics Inc

2.430

+0.070+2.97%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Vivos Therapeutics Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company shows very weak stock market performance, in line with its fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Vivos Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

138 / 210

Overall Ranking

329 / 4616

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

5.250

Target Price

+112.55%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Vivos Therapeutics Inc Highlights

StrengthsRisks

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. The Company calls its solution The Vivos Method. The Vivos Method represents the first clinically effective nonsurgical, noninvasive and nonpharmaceutical solution for treating mild to severe OSA. The Vivos Method includes treatment regimens that employ the proprietary Complete Airway Repositioning and/or Expansion (CARE) appliance therapy and other modalities that alter the size, shape and position of the soft tissues that comprise a patient's upper airway and/or palate. The Vivos Method comprises various products and services, including Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, and Vivos Airway Intelligence Service.

Growing

The company is in a growing phase, with the latest annual income totaling USD 15.03M.

Undervalued

The company’s latest PE is -2.02, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 766.93K shares, decreasing 8.43% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 547.00 shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 5.49, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 3.82M, representing a year-over-year decrease of 5.77%, while its net profit experienced a year-over-year decrease of 159.74%.

Score

Industry at a Glance

Previous score

5.49

Change



Financials

5.64

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.59

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.56

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.10

Key Metrics

Free cash flow

No Data

Vivos Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 8.23, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -2.02, which is -92.90% below the recent high of -0.14 and -194.48% above the recent low of -5.96.

Score

Industry at a Glance

Previous score

8.23

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 138/210

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 7.00, which is lower than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Vivos Therapeutics Inc is 5.25, with a high of 6.50 and a low of 4.00.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

5.250

Target Price

+122.46%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

110

Total

Median

Average

Company name

Ratings

Analysts

Vivos Therapeutics Inc

VVOS

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Dexcom Inc

DXCM

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 4.79, which is lower than the Healthcare Equipment & Supplies industry's average of 6.77. Sideways: Currently, the stock price is trading between the resistance level at 2.98 and the support level at 2.05, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.69

Change

0.1

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.032

Sell

RSI(14)

32.391

Neutral

STOCH(KDJ)(9,3,3)

7.663

Oversold

ATR(14)

0.213

High Vlolatility

CCI(14)

-118.626

Sell

Williams %R

89.404

Oversold

TRIX(12,20)

-1.073

Sell

StochRSI(14)

71.035

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

2.484

Sell

MA10

2.639

Sell

MA20

2.810

Sell

MA50

3.296

Sell

MA100

3.938

Sell

MA200

3.492

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.39. The latest institutional shareholding proportion is 10.22%, representing a quarter-over-quarter decrease of 69.13%. The largest institutional shareholder is The Vanguard, holding a total of 42.63K shares, representing 0.57% of shares outstanding, with 216.31% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Skaff (Michael C.)

828.00K

Luo (Dawei)

572.02K

V-CO Investors, L.L.C.

514.50K

Armistice Capital LLC

250.28K

Intracoastal Capital, L.L.C.

228.61K

UBS Financial Services, Inc.

142.80K

+7499.84%

Ionic Ventures LLC

83.00K

Huntsman (Ronald Kirk)

73.06K

Geode Capital Management, L.L.C.

57.90K

+0.96%

Cutter & Company, Inc.

49.10K

+28.87%

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 2.27, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 6.84. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.